TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12856482

Group type: EXPERIMENTAL
Intervention: Endogenous digoxin synthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dolichol levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ubiquinone levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free radical levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tryptophan catabolites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyrosine catabolites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endogenous morphine synthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholesterol:phospholipid ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycoconjugate levels of RBC membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemispheric dominance
Number of subjects: 0
Study: 10099861

Group type: EXPERIMENTAL
Intervention: Lamotrigine (dose gradually increased in steps of 25 mg up to 100 mg per day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 15
Study: 8733086

Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg.kg‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 1751665

Group type: EXPERIMENTAL
Intervention: AST‐120 (oral adsorbent composed of spherical porous carbon particles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 312708

Group type: EXPERIMENTAL
Intervention: morphine (2 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: halothane
Number of subjects: 16
Study: 30852783

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) with human-assisted social robot
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT) without human-assisted social robot
Number of subjects: 14
Study: 31154895

Group type: EXPERIMENTAL
Intervention: Free play
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Mixed activity
Number of subjects: 197

Group type: COMPARATOR
Intervention: Organized sessions
Number of subjects: 197
Study: 27768857

Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D3
Number of subjects: 448
Study: 25927723

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/d for 60 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23250357

Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21266377

Group type: EXPERIMENTAL
Intervention: Naltrexone treatment for 32 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo treatment for 32 weeks
Number of subjects: 78
Study: 19960133

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study: 17942341

Group type: EXPERIMENTAL
Intervention: Resilon/Ketac‐Endo/cold lateral compaction (group 8)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Resilon/AH Plus/cold lateral compaction (group 7)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Gutta‐percha, Epiphany/cold lateral compaction (group 3)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ketac‐Endo with gutta‐percha (group 2)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Gutta‐percha/Epiphany (group 3)
Number of subjects: 156
Study: 15236107

Group type: EXPERIMENTAL
Intervention: Manual endothelial cell enumeration
Number of subjects: 35

Group type: COMPARATOR
Intervention: Automatic endothelial cell enumeration using NAVIS(R) system
Number of subjects: 35
Study: 11524896

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychopharmacological interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 0
Study: 9502182

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rh-GH) 0.5-1.0 UIday(−1) s.c. at bed-time for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo for 6 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rh-GH)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 8063979

Group type: EXPERIMENTAL
Intervention: Psychodynamic‐interpersonal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive‐behavioral therapy
Number of subjects: 0
Study: 3175393

Group type: EXPERIMENTAL
Intervention: Anti-hypertensive agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 4689832

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 0
Study: 31982288

Group type: EXPERIMENTAL
Intervention: Zonisamide 25 mg/day
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Zonisamide 50 mg/day
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study: 30987269

Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 blockade therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glial cell expression of PD-L1
Number of subjects: 0
Study: 29161286

Group type: COMPARATOR
Intervention: Control (Glasses prescription only)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Free Glasses
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Free Glasses + $15 Upgrade
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Free Glasses + $30 Upgrade
Number of subjects: 882
Study: 25091163

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (30 cm segment)
Number of subjects: 20
Study: 23283526

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,000 mg plus pazopanib 400 mg (Cohort 1)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Lapatinib 1,500 mg monotherapy (Cohort 1)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,500 mg plus pazopanib 800 mg (Cohort 2)
Number of subjects: 190
Study: 21195327

Group type: EXPERIMENTAL
Intervention: Tympanoplasty with mastoidectomy (Group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tympanoplasty without mastoidectomy (Group B)
Number of subjects: 62
Study: 18983661

Group type: EXPERIMENTAL
Intervention: High-dose acetaminophen (6 g daily for 3 days), started within 12 hours after symptom onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study: 17598572

Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser
Number of subjects: 25
Study: 15033498

Group type: EXPERIMENTAL
Intervention: Psycho-educational booklet, self-help workbook, brief group CBT over a 9-month period
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Psycho-educational booklet, self-help workbook, brief group CBT
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Prognostic scale based on simple additive scoring
Number of subjects: 117

Group type: COMPARATOR
Intervention: Baseline severity measures
Number of subjects: 117
Study: 11245505

Group type: EXPERIMENTAL
Intervention: Chinese medicinal herbs (CMH)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 10193219

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.05 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atracurium 0.5 mg.kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mivacurium 0.15 mg.kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vecuronium 0.08 mg.kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg.kg‐1
Number of subjects: 0
Study: 8090943

Group type: EXPERIMENTAL
Intervention: Pacifiers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocking
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study: 2903955

Group type: EXPERIMENTAL
Intervention: Regular users of NSAIDs (12 patients)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non-regular users of NSAIDs (63 patients)
Number of subjects: 75
Study: 31420647

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200,000 IU initial dose followed by 100,000 IU monthly, n = 2558)
Number of subjects: 5110

Group type: COMPARATOR
Intervention: Placebo (n = 2552)
Number of subjects: 5110

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 5110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study: 31399140

Group type: EXPERIMENTAL
Intervention: Online intervention (Prevent 2nd Stroke - P2S)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Minimal care control group (email with Internet addresses of generic health sites)
Number of subjects: 530
Study: 29574292

Group type: EXPERIMENTAL
Intervention: Expanded insurance coverage
Number of subjects: 3121

Group type: EXPERIMENTAL
Intervention: Performance-based provider payments to improve quality
Number of subjects: 3121
Study: 26935961

Group type: COMPARATOR
Intervention: Standard CVCs
Number of subjects: 1859

Group type: EXPERIMENTAL
Intervention: Antibiotic CVCs
Number of subjects: 1859

Group type: EXPERIMENTAL
Intervention: Heparin CVCs
Number of subjects: 1859
Study: 25205139

Group type: EXPERIMENTAL
Intervention: Vitamin D₃ (cholecalciferol 4,000 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22429970

Group type: EXPERIMENTAL
Intervention: GlideScope® with Magill forceps
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: GlideScope® with Sponge forceps
Number of subjects: 28

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 28
Study: 19296055

Group type: EXPERIMENTAL
Intervention: Intervention group (healthy school food policy)
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1063
Study: 17303041

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% ointment
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 0.1% ointment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control preparations (Vanicream and petrolatum)
Number of subjects: 21
Study: 16244540

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Mechanical stapling
Number of subjects: 93
Study: 12049861

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (cisplatin 80 mg/m² by infusion over 4 h plus fluorouracil 1000 mg/m² daily by continuous infusion for 4 days) followed by surgical resection (CS group, n=400)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Surgical resection alone (S group, n=402)
Number of subjects: 802
Study: 9807602

Group type: EXPERIMENTAL
Intervention: Physiotherapy (manual lung hyperinflation and postural drainage)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no physiotherapy)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 8129118

Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg.kg‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg.kg‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flumazenil (300 micrograms) after midazolam
Number of subjects: 8
Study: 2530251

Group type: EXPERIMENTAL
Intervention: Acitretin 25 mg daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acitretin 50 mg daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acitretin 25 to 75 mg daily during open study
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30722719

Group type: EXPERIMENTAL
Intervention: Playground spaces that protect students from traffic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Playgrounds exposed to full sun
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unitary surface materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loose fill surfacing materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unitary surfaces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Playground equipment with loose strings or ropes
Number of subjects: 0
Study: 31697384

Group type: EXPERIMENTAL
Intervention: AS04‐HPV‐16/18 vaccine
Number of subjects: 12550

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12550
Study: 28350578

Group type: EXPERIMENTAL
Intervention: Demand-creation intervention package
Number of subjects: 10219

Group type: COMPARATOR
Intervention: Standard VMMC outreach alone (Control)
Number of subjects: 10219
Study: 26164769

Group type: EXPERIMENTAL
Intervention: SS + SUF
Number of subjects: 1096

Group type: COMPARATOR
Intervention: 3WSC
Number of subjects: 1096
Study: 23249256

Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Active self-ligating brackets
Number of subjects: 46
Study: 22015342

Group type: EXPERIMENTAL
Intervention: Chair yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational program
Number of subjects: 0
Study: 18755830

Group type: EXPERIMENTAL
Intervention: Patient preference for place of care
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Patient preference for place of death
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Agreement between patient and caregiver preferences for place of care
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Agreement between patient and caregiver preferences for place of death
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Actual place of death vs. preferences
Number of subjects: 71
Study: 17144438

Group type: EXPERIMENTAL
Intervention: MetaKenkoh game (Intervention Group - IG)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Monitoring only (Control Group - CG)
Number of subjects: 77
Study: 12680738

Group type: EXPERIMENTAL
Intervention: Ethanol (blood concentrations of approximately 80‐100 mg/100 ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 16
Study: 10731530

Group type: EXPERIMENTAL
Intervention: Naloxone (125 micrograms/kg i.v. bolus)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg p.o.)
Number of subjects: 32
Study: 9013372

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole-intolerant group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole-tolerant group
Number of subjects: 18
Study: 1364856

Group type: EXPERIMENTAL
Intervention: Artemether plus mefloquine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 35
Study: 2410328

Group type: EXPERIMENTAL
Intervention: ARA‐AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 29
Study: 30531676

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) and Sufentanil
Number of subjects: 100
Study: 26926681

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² IV on day 1 of a 3-week cycle (arm A)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² IV plus ramucirumab 10 mg/kg IV on day 1 of a 3-week cycle (arm B)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² IV on day 1 plus icrucumab 12 mg/kg IV on days 1 and 8 of a 3-week cycle (arm C)
Number of subjects: 140
Study: 24621807

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0
Study: 22357725

Group type: EXPERIMENTAL
Intervention: 3 × 20 g protein/d (20% pea, 20% soy, 30% egg, and 30% milk-protein isolate)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 3 × 20 g protein/d
Number of subjects: 99

Group type: COMPARATOR
Intervention: 3 × 20 g maltodextrin/d
Number of subjects: 99
Study: 20535042

Group type: EXPERIMENTAL
Intervention: Lateral decubitus position after caudal epidural injection (Group 1, n=28)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Supine position after caudal epidural injection (Group 2, n=29)
Number of subjects: 57
Study: 18473409

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (0.8 g/d) plus mesalamine (2.4 g/d)
Number of subjects: 37

Group type: COMPARATOR
Intervention: mesalamine plus placebo
Number of subjects: 37
Study: 15723220

Group type: COMPARATOR
Intervention: Docetaxel alone (treatment A)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Docetaxel with aprepitant (treatment B)
Number of subjects: 11
Study: 12706636

Group type: EXPERIMENTAL
Intervention: Reviparin-sodium
Number of subjects: 76

Group type: COMPARATOR
Intervention: UFH/OA
Number of subjects: 76
Study: 11052579

Group type: EXPERIMENTAL
Intervention: Planned caesarean section
Number of subjects: 2088

Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 2088
Study: 8782129

Group type: EXPERIMENTAL
Intervention: Vitamin D 50,000 units/week and calcium 1,000 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 1419761

Group type: EXPERIMENTAL
Intervention: terbinafine 1% cream applied for 1 day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: terbinafine 1% cream applied for 3, 5, or 7 consecutive days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: terbinafine 1% cream applied for 7 days
Number of subjects: 20
Study: 6371875

Group type: EXPERIMENTAL
Intervention: Trazodone (100-200 mg, nocte)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Mianserin (60-120 mg, nocte)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Mianserin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 125
Study: 31380684

Group type: EXPERIMENTAL
Intervention: Positive mood intervention (15-min video package)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Neutral control video
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Positive mood intervention
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study: 29983409

Group type: EXPERIMENTAL
Intervention: CCH injection
Number of subjects: 258

Group type: COMPARATOR
Intervention: ADH injection
Number of subjects: 258

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 258
Study: 27178983

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy for advanced NSCLC
Number of subjects: 22709
Study: 25151550

Group type: EXPERIMENTAL
Intervention: Colonoscopy with tone enhancement (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: White light colonoscopy (Group A)
Number of subjects: 80
Study: 22429765

Group type: EXPERIMENTAL
Intervention: Combined strengthening, stretching and functional training program, 12 weeks, twice a week, 40-60 minutes each session.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care (control group), details not specified.
Number of subjects: 0
Study: 20178889

Group type: EXPERIMENTAL
Intervention: Fascia iliaca block (FIB) (n = 51)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB) (n = 47)
Number of subjects: 98
Study: 17285514

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study: 16253099

Group type: EXPERIMENTAL
Intervention: CPF + CT
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: DP + CT
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: TUN-LAT + CT
Number of subjects: 3
Study: 12032789

Group type: EXPERIMENTAL
Intervention: Normal saline solution
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (clear amniotic fluid)
Number of subjects: 61
Study: 11105476

Group type: EXPERIMENTAL
Intervention: Confusing questions (negatives, double negatives, leading, multiple questions, complex syntax, and complex vocabulary)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simply phrased equivalents
Number of subjects: 0
Study: 9187187

Group type: EXPERIMENTAL
Intervention: Noninvasive assist-control ventilation (ACV)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Spontaneous breathing (SB)
Number of subjects: 15
Study: 1493431

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3541052

Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30827735

Group type: EXPERIMENTAL
Intervention: Active clinicians in middle-class communities after first interaction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active clinicians in middle-class communities after second interaction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control clinicians in middle-class communities
Number of subjects: 30
Study: 29710136

Group type: EXPERIMENTAL
Intervention: Physicians using an examination room computer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physicians not using an examination room computer
Number of subjects: 0
Study: 27769210

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (nab-P + Gem)
Number of subjects: 0

Group type: COMPARATOR
Intervention: gemcitabine (Gem)
Number of subjects: 0
Study: 24444353

Group type: EXPERIMENTAL
Intervention: PEG‐IFN therapy
Number of subjects: 119
Study: 22209798

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavioral therapy (TF-CBT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 26
Study: 20045278

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 1200
Study: 17564278

Group type: EXPERIMENTAL
Intervention: CPAP treatment for at least two years
Number of subjects: 35

Group type: COMPARATOR
Intervention: Untreated patients (refused CPAP therapy)
Number of subjects: 35
Study: 15982224

Group type: EXPERIMENTAL
Intervention: Nickel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0